Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of “Moderate Buy” from Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has been assigned an average rating of “Moderate Buy” from the twelve analysts that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $324.1111.

Several equities research analysts have recently weighed in on KRYS shares. Chardan Capital raised their target price on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Wall Street Zen raised Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Guggenheim raised their target price on Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Jefferies Financial Group raised their target price on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Finally, Citigroup raised their target price on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $299.45 on Friday. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $319.48. The firm has a market capitalization of $8.83 billion, a PE ratio of 40.03 and a beta of 0.50. The stock’s 50-day simple moving average is $272.14 and its 200-day simple moving average is $257.06.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The business had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. On average, sell-side analysts forecast that Krystal Biotech will post 7.98 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the transaction, the chief accounting officer owned 22,366 shares of the company’s stock, valued at $5,985,141.60. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Daniel Janney sold 37,895 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $266.88, for a total value of $10,113,417.60. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 97,714 shares of company stock valued at $26,183,109 over the last quarter. Company insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. EFG Asset Management North America Corp. increased its position in Krystal Biotech by 18.4% during the third quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock worth $4,784,000 after buying an additional 4,217 shares during the period. Public Sector Pension Investment Board increased its holdings in shares of Krystal Biotech by 15.9% in the third quarter. Public Sector Pension Investment Board now owns 100,431 shares of the company’s stock valued at $17,729,000 after purchasing an additional 13,743 shares during the period. SG Americas Securities LLC increased its holdings in shares of Krystal Biotech by 469.9% in the fourth quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock valued at $4,662,000 after purchasing an additional 15,591 shares during the period. Atle Fund Management AB increased its holdings in shares of Krystal Biotech by 109.3% in the third quarter. Atle Fund Management AB now owns 42,191 shares of the company’s stock valued at $7,448,000 after purchasing an additional 22,033 shares during the period. Finally, William Blair Investment Management LLC increased its holdings in shares of Krystal Biotech by 63.9% in the third quarter. William Blair Investment Management LLC now owns 149,302 shares of the company’s stock valued at $26,356,000 after purchasing an additional 58,203 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.